US4632979A - Therapeutic LHRH analogs - Google Patents

Therapeutic LHRH analogs Download PDF

Info

Publication number
US4632979A
US4632979A US06/621,673 US62167384A US4632979A US 4632979 A US4632979 A US 4632979A US 62167384 A US62167384 A US 62167384A US 4632979 A US4632979 A US 4632979A
Authority
US
United States
Prior art keywords
trp
boc
phe
leu
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/621,673
Inventor
David H. Coy
Jacques-Pierre Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Assigned to ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, NEW ORLEANS, LA A STATE AGENCY reassignment ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, NEW ORLEANS, LA A STATE AGENCY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: COY, DAVID H., MOREAU, JACQUES-PIERRE
Priority to US06/621,673 priority Critical patent/US4632979A/en
Priority to JP59252799A priority patent/JPS617297A/en
Priority to DK615084A priority patent/DK615084A/en
Priority to EP84309021A priority patent/EP0171477A3/en
Priority to FI850193A priority patent/FI850193L/en
Priority to NO852439A priority patent/NO852439L/en
Priority to NZ212454A priority patent/NZ212454A/en
Priority to CA000484283A priority patent/CA1257950A/en
Priority to ZA854590A priority patent/ZA854590B/en
Priority to AU43764/85A priority patent/AU4376485A/en
Priority to ES544316A priority patent/ES8702438A1/en
Priority to PT80658A priority patent/PT80658B/en
Publication of US4632979A publication Critical patent/US4632979A/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Definitions

  • This invention relates to amino acid-containing therapeutic compounds.
  • Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are gonadotropic hormones produced by the pituitary gland of humans and animals. LH and FSH are released from the pituitary gland by the action of LH- and FSH-releasing hormone (LHRH).
  • LHRH LH- and FSH-releasing hormone
  • Naturally-occuring LHRH has been shown to be a decapeptide of the formula (pyro)-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 ; A. V. Schally et al., Biochem. Biophys. Res. Comm., 43, 393 and 1334 (1971). (Herein, where no isomeric designation is given, the naturally occurring L-form is meant.)
  • LHRH analogs and their use in various medical applications.
  • Schally and Coy U.S. Pat. No. 4,010,125 describes a decapeptide analogue of LHRH of the formula (pyro)-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH 2 useful for inducing ovulation and for treating delayed puberty and hypogonadism.
  • the invention features compounds having the formula K-His-Trp-Ser-Tyr-M-Q-Arg-Pro-T, wherein K is N-acetyl-Sarcosine or pGlu; M is D-Phe, D-Trp, D- ⁇ -Napthylalanine, or D-4-X-Phe, wherein X is OH, F, Cl, Br, or Me; Q is Leu, Phe, 4-X-Phe, Trp, or ⁇ -Napthylalanine, wherein X is as defined above, or an N-Me-derivative thereof; and T is Gly-NH 2 , NHCH 3 , NHCH 2 CH 3 , or NHCH 2 CH 2 CH 3 ; provided that, when Q is Leu or N-Me-Leu, K cannot be pGlu; or a pharmaceutically acceptable salt thereof.
  • Preferred compounds of the invention are N-Acetyl-Sarcosine-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-NHCH 2 CH 3 ; pGlu-His-Trp-Ser-Tyr-D-Phe-Phe-Arg-Pro-Gly-NH 2 ; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NHCH 2 CH 3 ; N-Acetyl-Sar-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHCH 2 CH 3 ; and N-Acetyl-Sar-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH 2 .
  • a therapeutically effective amount of the therapeutic compound and a pharmaceutically acceptable carrier substance e.g. a sterile aqueous vehicle which may also contain other solutes such as buffers or preservatives, polyethyleneglycol, lactose, or silica, together form a therapeutic composition e.g. a pill, tablet, or capsule for oral administration to a human patient, a powder or liquid capable of being administered nasally as drops of spray, or a solid or liquid carrier capable of being injected intramuscularly or implanted for prolonged periods of time in long-acting, slow release, or depot dosage forms.
  • a pharmaceutically acceptable carrier substance e.g. a sterile aqueous vehicle which may also contain other solutes such as buffers or preservatives, polyethyleneglycol, lactose, or silica
  • the pill, tablet or capsule can be coated with a substance capable of protecting the composition from the gastric acid in the patient's stomach for a period of time sufficient to allow the composition to pass undisintegrated into the patient's small intestine.
  • the compounds of the invention can be effective in treating hormone-dependent cancers as well as alleviating the adverse effects of chemotherapy-induced hormone suppression. Furthermore, their low molecular weight facilitates administration and absorption.
  • the compounds of the invention have the general formula recited in the Summary of the Invention above. Examples of preferred compounds within the general formula are those referred to as preferred embodiments above.
  • the compounds are nonapeptide or decapeptide LHRH analogs.
  • the compounds can be provided in the form of acid addition salts, e.g., salts of organic acids, such as acetic, lactic, succinic, benzoic, salicyclic, methanesulfonic or toluenesulfonic acid; polymeric acids such as tannic acid or carboxymethyl cellulose; and inorganic acids such as hydrohalic acids, e.g., hydrochloric acid, sulfuric acid, or phosphoric acid.
  • organic acids such as acetic, lactic, succinic, benzoic, salicyclic, methanesulfonic or toluenesulfonic acid
  • polymeric acids such as tannic acid or carboxymethyl cellulose
  • inorganic acids such as hydrohalic acids, e.g., hydrochloric acid, sulfuric acid, or phosphoric acid.
  • a particular acid addition salt can be converted into another acid addition salt, e.g. a salt with a non-toxic, pharmaceutically acceptable acid, by treatment with the appropriate ion exchange resin, e.g., in the manner described in Boisonnas et al., Helv. Chim. Acta, 43, 1349 (1960), hereby incorporated by reference.
  • Suitable ion exchange resins are cellulose based cation exchangers, e.g., carboxymethylcellulose or chemically modified, cross linked dextran cation exchangers (such as Sephadex C-type), and strongly basic anion exchange resins, (such as those listed in Greenstein et al., "Chemistry of the Amino Acids", John Wiley and Sons, Inc., New York and London, 1961, Vol. 2, p. 1456).
  • the compounds of the invention can be prepared using solid phase synthesis. Synthesis is preferably commenced at the C-terminal end of the peptide using an ⁇ -amino protected resin of the C-terminal amino acid. Such a starting material is prepared by attaching an ⁇ -amino protected proline or glycine (depending on the peptide) to a benzhydrylamine resin, or a chloromethylated resin.
  • a benzhydrylamine resin is described in Rivaille et al., Helv. Chim. Acta, 54, 2772 (1971) and the chloromethylated resin is commercially available from BioRad Laboratories, Richmond, Calif.
  • an amide anchoring bond is formed with the ⁇ -amino protected amino acid as follows: ##STR1## This permits the C-terminal amide function to be obtained directly after the synthesis of the amino acid sequence has been completed, by cleaving off the resin support of the linked peptide to form the amide at the C-terminal portion of the desired peptide.
  • the use of hydrogen fluoride for cleaving off the resin support also advantageously removes the side chain protective groups.
  • the anchoring bond is the benzylester group.
  • a convenient procedure for converting the linked protected peptide to the C-terminal amide is to immonolize the protected peptide off the resin and then remove the protective groups of the resulting amide by treatment with sodium and liquid ammonia or by hydrogen fluoride cleavage.
  • An alternative procedure is to cleave by transesterification with a lower alkanol, preferably methanol or ethanol. In the presence of triethylamine and then convert the resulting ester into an amide and subsequently deprotect as described above.
  • an ⁇ -amino protected glycine preferably t-butyloxy-carbonylglycine (boc-gly)
  • a carboxyl group activating compound preferably dicyclohexylcarbodiimide.
  • the ⁇ -amino protecting group is removed, e.g., using trifluoroacetic acid in methylene chloride, trifluoroacetic acid alone, or hydrochloric acid in dioxane. Deprotection is carried out at a temperature between about 0° C.
  • the remaining ⁇ -amino protecting amino acids are coupled step-wise in the desired order to obtain the desired peptide.
  • Each protected amino acid is introduced into the solid phase reactor in about a three-fold excess and coupling is carried out in methylene chloride or dimethylformamide in methylene chloride.
  • the coupling procedure is repeated before removal of the ⁇ -amino protecting group, prior to the coupling of the next amino acid to the sollid phase reactor.
  • the success of the coupling reaction at each stage of the synthesis can be monitored by the ninhydrin reaction, as described in Kaiser et al., Analyt. Biochem. 34, 595 (1970).
  • Boc-Pro is esterified to chloromethylbenzyl-poly-styrene resin (1% cross-linked with divinylbenzene) (Bio Rad) to give a Boc-Pro-resin with an incorporation of 0.5 mmole of Pro per gram.
  • This resin (2.0 g, 1.0 mmole) is placed in the reaction vessel of a Beckman 990 automatic peptide synthesizer programmed to carry out the following work-wash cycle: (a) CH 2 Cl 2 ; (b) 33% trifluoroacetic acid in CH 2 Cl 2 (2 times for 1 min. and 25 min. each); (c) CH 2 Cl 2 ; (d) C 2 H 5 OH; (e) CH 2 Cl 2 ; (f) 10% (C 2 H 5 ) 3 N in CH 2 Cl 2 .
  • the neutralized resin is stirred with Boc-N G -tosyl-arginine [Boc-Arg(Tos)] and diisopropylcarbodiimide (3.0 mmole) in CH 2 Cl 2 for 1 h and the resulting amino acid resin is then cycled through steps (a) through (g) in the above wash program.
  • the following amino acids (3.0 mmole) are then coupled successively by the same reaction cycle: Boc-Leu, Boc-D-Phe, Boc-Tyr, Boc-Ser(Bzl), Boc-Trp, Boc-His(Tosyl), acetyl Sar.
  • the completed peptide-resin (3.71 g) is then suspended in DMF (20 ml) to which is added ethylamine (5 ml) at 0° C. The mixture is stirred at room temperature and filtered to remove spent resin. The filtrate is evaporated to a yellow oil which solidifies to give the protected peptide as an off-white powder (590 mg).
  • the above protected peptide (590 mg) is mixed with anisole (4 ml), dithiothreitol (100 mg) and anhydrous hydrogen fluoride (36 ml) at 0° C. and stirred for 45 min. Excess hydrogen fluoride is evaporated rapidly under a stream of dry nitrogen and the free peptide is precipitated and washed with ether. The peptide is then dissolved in a minimum volume of 2M AcOH and eluted on a column (2.5 ⁇ 100 cm) of Sephadex G-25. Fractions containing a major peak observed at 280 nm are pooled and lyophilized.
  • the product is found to be homogeneous by thin layer chromatography in 4 solvent systems on silica gel plates. Amino acid analysis of an acid hydrolysate confirms the composition of the peptide.
  • the above peptide is prepared in the same fashion as N-Ac-Sar-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-NHCH 3 CH 3 by using Boc-D-Trp instead of Boc-D-Phe during the amino acid coupling step.
  • Benzhydrylamine polystyrene resin (Bachem, Inc.) (1.58 g, 0.50 mmole) in the chloride ion form is placed in the reaction vessel of the automatic peptide synthesizer and subjected to the work-wash cycle described above.
  • the following amino acids (1.5 mmole) are then coupled under the conditions described above: Boc-Gly, Boc-Pro, Boc-Arg (Tos), Boc-Phe, Boc-D-Phe, Boc-Tyr, Boc-Trp, Boc-His (Tos), pGlu.
  • the completed resin weights 2.06 g.
  • the resin is cleaved by the hydrogen fluoride treatment described above and the free peptide is extracted into a minimum volume of 2M AcOH.
  • the purification schedule described above then gives pure peptide (140 mg) as a white, fluffy powder.
  • Benzhydrylamine polystyrene resin (Bachem, Inc.) (1.58 g, 0.50 mmole) in the chloride ion form is placed in the reaction vessel of the automatic peptide synthesizer and subjected to the work-wash cycle described above. The following amino acids (1.5 mmole) are then coupled under the standard conditions. Boc-Gly, Boc-Pro, Boc Arq (Tos), Boc-Leu, Boc-D-Trp, Boc-His (Tos), acetyl Sar. The completed resin weights 2.10 g.
  • the resin is cleaved by the hydrogen fluoride treatment described above and is purified as described above to give 152 mg of the pure compound as a white, fluffly powder.
  • This decapeptide is prepared in a manner analogous to those described above.
  • the peptides can be used to treat reproductive system-related disorders, e.g., precocious puberty.
  • the peptides can also be administered to male sex offenders to decrease testosterone levels and thus diminish sex drive, and to humans, preferably women, as a contraceptive.
  • the peptides can also be used to minimize deleterious effects during chemotherapy treatment for cancer by temporarily and reversibly suppressing hormone levels.
  • the peptides can also be used to treat endometriosis, pencreatic cancer, and hormone-dependent cancers, e.g. prostate, breast, thyroid, and ovarian cancer.
  • a hormone-dependent cancer is a cancer whose virulence can vary with hormone level.
  • the peptides can also be used to treat benign prostrate hyperplasia.
  • the mechanism by which the compounds inhibit tumor growth is believed to be either inhibition of trophic hormones such as testosterone, or a direct effect on the tumor itself.
  • An advantage of the compounds is that they can lower testosterone levels in mammals over time while causing a fairly low initial "flare up", or increase, in testosterone levels.
  • the mode of administration of the peptides may vary with use.
  • the preferred mode of administration for treatment of cancer will be to include the peptide in an implant of, e.g. a biodegradable polymer, which is transdermally implanted in the cancer patient for prolonged release of the peptide over time.
  • Dosage will also vary with application, and will generally be higher for cancer therapy than for contraceptive and other therapeutic uses.
  • the dosage for non-cancer use will be between 1 and 50 micrograms/kg/day, preferably about 10 micrograms/kg/day.
  • Dosage for treatment of cancer will be between 10 and 500 micrograms/kg/day, preferably about 100 micrograms/kg/day.

Abstract

A compound having the formula K-His-Trp-Ser-Tyr-M-Q-Arg-Pro-T, wherein K is N-Acetyl-Sarconsine or pGlu; is D-Phe, D-Trp, D-β-Naphthylalanine, or D-4-X-Phe, wherein X is OH, F, Cl, Br, or Me; Q is Leu, Phe, 4-X-Phe, Trp, or β-Naphthylamine (wherein X is OH, F, Cl, Br, or Me), or an N-Me-derivative thereof; and T is Gly-NH2, NHCH3, NHCH2 CH3, or NHCH2 CH2 CH3 ; provided that, when Q is Leu or N-Me-Leu, K cannot be pGlu; or a pharmaceutically acceptable salt thereof.

Description

BACKGROUND OF THE INVENTION
This invention relates to amino acid-containing therapeutic compounds.
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are gonadotropic hormones produced by the pituitary gland of humans and animals. LH and FSH are released from the pituitary gland by the action of LH- and FSH-releasing hormone (LHRH). Naturally-occuring LHRH has been shown to be a decapeptide of the formula (pyro)-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 ; A. V. Schally et al., Biochem. Biophys. Res. Comm., 43, 393 and 1334 (1971). (Herein, where no isomeric designation is given, the naturally occurring L-form is meant.)
A large number of patents and publications described LHRH analogs and their use in various medical applications. For example, Schally and Coy U.S. Pat. No. 4,010,125 describes a decapeptide analogue of LHRH of the formula (pyro)-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 useful for inducing ovulation and for treating delayed puberty and hypogonadism.
Tolis et al. Proc. Natl. Acad. Sci. 79, 1658-1662 (1982) suggests that the chronic administration of large doses of two LHRH analogues ([D-Trp6 ] LHRH and [D-Ser(But)6 ]des-Gly-NH2 10 -LHRH) can result in the suppression of pituitary and leydig cell production and the regression of mammary and prostatic endocrine-dependent tumors in animals and humans.
Johnson et al. U.S. Pat. No. 4,071,622 describes nonapeptides of the formula pGlu-His-Trp-Ser-Tyr-X-Leu-Arg-Pro-NH-C2 H5, where X is the D form of Tyr, Trp, or Phe, useful for the treatment of mammary tumors.
SUMMARY OF THE INVENTION
In general, the invention features compounds having the formula K-His-Trp-Ser-Tyr-M-Q-Arg-Pro-T, wherein K is N-acetyl-Sarcosine or pGlu; M is D-Phe, D-Trp, D-β-Napthylalanine, or D-4-X-Phe, wherein X is OH, F, Cl, Br, or Me; Q is Leu, Phe, 4-X-Phe, Trp, or β-Napthylalanine, wherein X is as defined above, or an N-Me-derivative thereof; and T is Gly-NH2, NHCH3, NHCH2 CH3, or NHCH2 CH2 CH3 ; provided that, when Q is Leu or N-Me-Leu, K cannot be pGlu; or a pharmaceutically acceptable salt thereof.
Preferred compounds of the invention are N-Acetyl-Sarcosine-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-NHCH2 CH3 ; pGlu-His-Trp-Ser-Tyr-D-Phe-Phe-Arg-Pro-Gly-NH2 ; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NHCH2 CH3 ; N-Acetyl-Sar-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHCH2 CH3 ; and N-Acetyl-Sar-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2.
In other preferred embodiments, a therapeutically effective amount of the therapeutic compound and a pharmaceutically acceptable carrier substance, e.g. a sterile aqueous vehicle which may also contain other solutes such as buffers or preservatives, polyethyleneglycol, lactose, or silica, together form a therapeutic composition e.g. a pill, tablet, or capsule for oral administration to a human patient, a powder or liquid capable of being administered nasally as drops of spray, or a solid or liquid carrier capable of being injected intramuscularly or implanted for prolonged periods of time in long-acting, slow release, or depot dosage forms.
The pill, tablet or capsule can be coated with a substance capable of protecting the composition from the gastric acid in the patient's stomach for a period of time sufficient to allow the composition to pass undisintegrated into the patient's small intestine.
The compounds of the invention can be effective in treating hormone-dependent cancers as well as alleviating the adverse effects of chemotherapy-induced hormone suppression. Furthermore, their low molecular weight facilitates administration and absorption.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
DESCRIPTION OF THE PREFERRED EMBODIMENT Structure
The compounds of the invention have the general formula recited in the Summary of the Invention above. Examples of preferred compounds within the general formula are those referred to as preferred embodiments above.
The compounds are nonapeptide or decapeptide LHRH analogs. The compounds can be provided in the form of acid addition salts, e.g., salts of organic acids, such as acetic, lactic, succinic, benzoic, salicyclic, methanesulfonic or toluenesulfonic acid; polymeric acids such as tannic acid or carboxymethyl cellulose; and inorganic acids such as hydrohalic acids, e.g., hydrochloric acid, sulfuric acid, or phosphoric acid.
If desired, a particular acid addition salt can be converted into another acid addition salt, e.g. a salt with a non-toxic, pharmaceutically acceptable acid, by treatment with the appropriate ion exchange resin, e.g., in the manner described in Boisonnas et al., Helv. Chim. Acta, 43, 1349 (1960), hereby incorporated by reference. Suitable ion exchange resins are cellulose based cation exchangers, e.g., carboxymethylcellulose or chemically modified, cross linked dextran cation exchangers (such as Sephadex C-type), and strongly basic anion exchange resins, (such as those listed in Greenstein et al., "Chemistry of the Amino Acids", John Wiley and Sons, Inc., New York and London, 1961, Vol. 2, p. 1456).
Synthesis
The compounds of the invention can be prepared using solid phase synthesis. Synthesis is preferably commenced at the C-terminal end of the peptide using an α-amino protected resin of the C-terminal amino acid. Such a starting material is prepared by attaching an α-amino protected proline or glycine (depending on the peptide) to a benzhydrylamine resin, or a chloromethylated resin. The preparation of the benzhydrylamine resin is described in Rivaille et al., Helv. Chim. Acta, 54, 2772 (1971) and the chloromethylated resin is commercially available from BioRad Laboratories, Richmond, Calif.
In using the benzhydrylamine resin, an amide anchoring bond is formed with the α-amino protected amino acid as follows: ##STR1## This permits the C-terminal amide function to be obtained directly after the synthesis of the amino acid sequence has been completed, by cleaving off the resin support of the linked peptide to form the amide at the C-terminal portion of the desired peptide. In this instance the use of hydrogen fluoride for cleaving off the resin support also advantageously removes the side chain protective groups.
When chloromethylated resin is used, the anchoring bond is the benzylester group. In this instance a convenient procedure for converting the linked protected peptide to the C-terminal amide is to immonolize the protected peptide off the resin and then remove the protective groups of the resulting amide by treatment with sodium and liquid ammonia or by hydrogen fluoride cleavage. An alternative procedure is to cleave by transesterification with a lower alkanol, preferably methanol or ethanol. In the presence of triethylamine and then convert the resulting ester into an amide and subsequently deprotect as described above.
More specifically, to make peptides having a C-terminal glycine, an α-amino protected glycine, preferably t-butyloxy-carbonylglycine (boc-gly), is coupled to benzhydrolamine resin with the aid of a carboxyl group activating compound, preferably dicyclohexylcarbodiimide. Following the coupling of the α-amino protected glycine to the resin support, the α-amino protecting group is removed, e.g., using trifluoroacetic acid in methylene chloride, trifluoroacetic acid alone, or hydrochloric acid in dioxane. Deprotection is carried out at a temperature between about 0° C. and room temperature. Other standard cleaving reagents and conditions for removal of specific α-amino protecting groups can be used, as described in Schroder et al., "The Peptides", Vol. 1, Academic Press, New York, 1965, pp. 72-75.
After removal of the α-amino protecting group, the remaining α-amino protecting amino acids are coupled step-wise in the desired order to obtain the desired peptide. Each protected amino acid is introduced into the solid phase reactor in about a three-fold excess and coupling is carried out in methylene chloride or dimethylformamide in methylene chloride. In cases where incomplete coupling occurs, the coupling procedure is repeated before removal of the α-amino protecting group, prior to the coupling of the next amino acid to the sollid phase reactor. The success of the coupling reaction at each stage of the synthesis can be monitored by the ninhydrin reaction, as described in Kaiser et al., Analyt. Biochem. 34, 595 (1970).
Although a solid phase synthesis of the peptides is preferred, classical methods can also be used, as described, e.g., in Immer et al. U.S. Pat. No. 3,853,108.
Specific compounds are prepared as follows.
N-acetyl-sarcosine-Nim -tosyl-histidine-tryptophan-O-benzyl-serine-tyrosine-D-phenylalanine-leucine-NG -tosyl-arginine-proline-ethylamide
Boc-Pro is esterified to chloromethylbenzyl-poly-styrene resin (1% cross-linked with divinylbenzene) (Bio Rad) to give a Boc-Pro-resin with an incorporation of 0.5 mmole of Pro per gram.
This resin (2.0 g, 1.0 mmole) is placed in the reaction vessel of a Beckman 990 automatic peptide synthesizer programmed to carry out the following work-wash cycle: (a) CH2 Cl2 ; (b) 33% trifluoroacetic acid in CH2 Cl2 (2 times for 1 min. and 25 min. each); (c) CH2 Cl2 ; (d) C2 H5 OH; (e) CH2 Cl2 ; (f) 10% (C2 H5)3 N in CH2 Cl2.
The neutralized resin is stirred with Boc-NG -tosyl-arginine [Boc-Arg(Tos)] and diisopropylcarbodiimide (3.0 mmole) in CH2 Cl2 for 1 h and the resulting amino acid resin is then cycled through steps (a) through (g) in the above wash program. The following amino acids (3.0 mmole) are then coupled successively by the same reaction cycle: Boc-Leu, Boc-D-Phe, Boc-Tyr, Boc-Ser(Bzl), Boc-Trp, Boc-His(Tosyl), acetyl Sar. The completed peptide-resin (3.71 g) is then suspended in DMF (20 ml) to which is added ethylamine (5 ml) at 0° C. The mixture is stirred at room temperature and filtered to remove spent resin. The filtrate is evaporated to a yellow oil which solidifies to give the protected peptide as an off-white powder (590 mg).
N-Ac-sarcosine-histidine-tyrptophan-serine-tyrosine-D-phenylalanine-leucine-arginine-proline-ethylamide
The above protected peptide (590 mg) is mixed with anisole (4 ml), dithiothreitol (100 mg) and anhydrous hydrogen fluoride (36 ml) at 0° C. and stirred for 45 min. Excess hydrogen fluoride is evaporated rapidly under a stream of dry nitrogen and the free peptide is precipitated and washed with ether. The peptide is then dissolved in a minimum volume of 2M AcOH and eluted on a column (2.5×100 cm) of Sephadex G-25. Fractions containing a major peak observed at 280 nm are pooled and lyophilized. This material is then applied to a column (2.5×50 mm) of Whatman octadecylsilane-silica (LRP-1, 15-20 μM) which is eluted with a linear gradient of 10-50% acetonitrile-0.1% trifluoroacetic acid in water. Fractions are examined by thin layer chromatography and high pressure liquid chromatography and pooled to give maximum purity. Lyophilization of the solution gives 138 mg of the product as a fluffy white powder.
The product is found to be homogeneous by thin layer chromatography in 4 solvent systems on silica gel plates. Amino acid analysis of an acid hydrolysate confirms the composition of the peptide.
N-Acetyl-sarcosine-histidine-tryptophan-serine-tyrosine-D-tryptophan-leucine-arginine-proline-ethylamide
The above peptide is prepared in the same fashion as N-Ac-Sar-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-NHCH3 CH3 by using Boc-D-Trp instead of Boc-D-Phe during the amino acid coupling step.
Pyroglutamic acid-histidine-tryptophan-serine-tyrosine-D-phenylalanine-phenylalanine-arginine-proline-glycine-amide
Benzhydrylamine polystyrene resin (Bachem, Inc.) (1.58 g, 0.50 mmole) in the chloride ion form is placed in the reaction vessel of the automatic peptide synthesizer and subjected to the work-wash cycle described above. The following amino acids (1.5 mmole) are then coupled under the conditions described above: Boc-Gly, Boc-Pro, Boc-Arg (Tos), Boc-Phe, Boc-D-Phe, Boc-Tyr, Boc-Trp, Boc-His (Tos), pGlu. The completed resin weights 2.06 g.
The resin is cleaved by the hydrogen fluoride treatment described above and the free peptide is extracted into a minimum volume of 2M AcOH. The purification schedule described above then gives pure peptide (140 mg) as a white, fluffy powder.
This material is found to be homogeneous by analytical thin layer chromatography in 4 solvent systems on silica gel plates. Amino acid analysis of an acid hydrolysate confirms the composition of the peptide.
N-Acetyl-sarcosine-histidine-tryptophan-serine-tyrosine-D-tryptophan-leucine-arginine-proline-glycine-amide
Benzhydrylamine polystyrene resin (Bachem, Inc.) (1.58 g, 0.50 mmole) in the chloride ion form is placed in the reaction vessel of the automatic peptide synthesizer and subjected to the work-wash cycle described above. The following amino acids (1.5 mmole) are then coupled under the standard conditions. Boc-Gly, Boc-Pro, Boc Arq (Tos), Boc-Leu, Boc-D-Trp, Boc-His (Tos), acetyl Sar. The completed resin weights 2.10 g.
The resin is cleaved by the hydrogen fluoride treatment described above and is purified as described above to give 152 mg of the pure compound as a white, fluffly powder.
This material is found to be homogeneous by analytical thin layer chromatography in 4 solvent systems. Amino acid analysis of an acid hydrolysate conforms the composition of the peptide.
pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NHCH2 CH3
This decapeptide is prepared in a manner analogous to those described above.
Use
The peptides of the invention can be administered, preferably in the form of an acid addition salt in combination with a pharmaceutically acceptable carrier substance, to a human or animal patient in need of such peptide. An effective amount of the peptide can be administered systemically, either by intravenous, subcutaneous, or intramuscular injection, or by any other medically acceptable method, e.g., by oral, sublingual, or nasal administration.
The peptides can be used to treat reproductive system-related disorders, e.g., precocious puberty. The peptides can also be administered to male sex offenders to decrease testosterone levels and thus diminish sex drive, and to humans, preferably women, as a contraceptive. The peptides can also be used to minimize deleterious effects during chemotherapy treatment for cancer by temporarily and reversibly suppressing hormone levels. The peptides can also be used to treat endometriosis, pencreatic cancer, and hormone-dependent cancers, e.g. prostate, breast, thyroid, and ovarian cancer. (A hormone-dependent cancer is a cancer whose virulence can vary with hormone level.) The peptides can also be used to treat benign prostrate hyperplasia.
The mechanism by which the compounds inhibit tumor growth is believed to be either inhibition of trophic hormones such as testosterone, or a direct effect on the tumor itself.
An advantage of the compounds is that they can lower testosterone levels in mammals over time while causing a fairly low initial "flare up", or increase, in testosterone levels.
The mode of administration of the peptides may vary with use. For example, the preferred mode of administration for treatment of cancer will be to include the peptide in an implant of, e.g. a biodegradable polymer, which is transdermally implanted in the cancer patient for prolonged release of the peptide over time.
Dosage will also vary with application, and will generally be higher for cancer therapy than for contraceptive and other therapeutic uses. Generally, the dosage for non-cancer use will be between 1 and 50 micrograms/kg/day, preferably about 10 micrograms/kg/day. Dosage for treatment of cancer will be between 10 and 500 micrograms/kg/day, preferably about 100 micrograms/kg/day.
Other embodiments are within the following claims.

Claims (4)

We claim:
1. The compound having the formula N-Ac-Sarc-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-NHCH2 CH3.
2. The compound having the formula pGlu-His-Trp-Ser-Tyr-D-Phe-Phe-Arg-Pro-Gly-NH2.
3. The compound having the formula N-Ac-Sar-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2.
4. The compound having the formula N-Ac-Sar-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHCH2 CH3.
US06/621,673 1984-06-18 1984-06-18 Therapeutic LHRH analogs Expired - Fee Related US4632979A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US06/621,673 US4632979A (en) 1984-06-18 1984-06-18 Therapeutic LHRH analogs
JP59252799A JPS617297A (en) 1984-06-18 1984-11-29 Therapeutical lhrh analogue
DK615084A DK615084A (en) 1984-06-18 1984-12-20 LHRH ANALOGUE FOR THERAPEUTIC USE AND PREPARATION CONTAINING SUCH A HORMONIC COMPOUND
EP84309021A EP0171477A3 (en) 1984-06-18 1984-12-21 Amino acid-containing therapeutic compounds
FI850193A FI850193L (en) 1984-06-18 1985-01-16 THERAPEUTIC LHRH ANALOGER.
NO852439A NO852439L (en) 1984-06-18 1985-06-17 AMINO ACIDAL COMPOUNDS.
NZ212454A NZ212454A (en) 1984-06-18 1985-06-18 Therapeutic lhrh analogues
CA000484283A CA1257950A (en) 1984-06-18 1985-06-18 Therapeutic lhrh analogs
ZA854590A ZA854590B (en) 1984-06-18 1985-06-18 Amino acid-containing therapeutic compounds
AU43764/85A AU4376485A (en) 1984-06-18 1985-06-18 Therapeutic lhrh analogues
ES544316A ES8702438A1 (en) 1984-06-18 1985-06-18 Amino acid-containing therapeutic compounds.
PT80658A PT80658B (en) 1984-06-18 1985-06-18 Process for the preparation of amino-acids and therapeutic method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/621,673 US4632979A (en) 1984-06-18 1984-06-18 Therapeutic LHRH analogs

Publications (1)

Publication Number Publication Date
US4632979A true US4632979A (en) 1986-12-30

Family

ID=24491153

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/621,673 Expired - Fee Related US4632979A (en) 1984-06-18 1984-06-18 Therapeutic LHRH analogs

Country Status (12)

Country Link
US (1) US4632979A (en)
EP (1) EP0171477A3 (en)
JP (1) JPS617297A (en)
AU (1) AU4376485A (en)
CA (1) CA1257950A (en)
DK (1) DK615084A (en)
ES (1) ES8702438A1 (en)
FI (1) FI850193L (en)
NO (1) NO852439L (en)
NZ (1) NZ212454A (en)
PT (1) PT80658B (en)
ZA (1) ZA854590B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
WO1989007450A1 (en) * 1988-02-10 1989-08-24 Abbott Laboratories Lhrh analogs
US5084443A (en) * 1989-12-04 1992-01-28 Biomeasure, Inc. Promoting expression of acetylcholine receptors with lhrh antagonist
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
AT397035B (en) * 1987-09-21 1994-01-25 Debiopharm Sa BIOERODABLE PHARMACEUTICAL COMPOSITION FOR LASTING AND CONTROLLED POLYPEPTIDE RELEASE
US5284657A (en) * 1991-08-26 1994-02-08 Abbott Laboratories Compositions and methods for the sublingual or buccal administration of therapeutic agents
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ213759A (en) * 1984-10-19 1989-01-27 Genentech Inc Lhrh-ctp protein conjugates influencing prolactin fsh and lh release
ZA862570B (en) * 1985-04-09 1986-12-30 Univ Tulane Therapeutic decapeptides
JP2672677B2 (en) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド LHRH homolog
CA2036657C (en) * 1990-02-20 2003-02-11 John J. Nestor, Jr. Temporary minimal protection synthesis of lh-rh analogs
AU2009259033B2 (en) 2008-06-12 2013-11-07 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4010149A (en) * 1974-04-26 1977-03-01 Sankyo Company Limited Analogs of LH-RH and process for preparing the same
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4034082A (en) * 1976-03-01 1977-07-05 Abbott Laboratories Method to prevent reproduction in warm-blooded female animals with nonapeptides
US4071622A (en) * 1976-02-11 1978-01-31 Abbott Laboratories Treatment of a mammary or DMBA inducible tumor
US4218439A (en) * 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4321260A (en) * 1980-05-22 1982-03-23 Ayerst, Mckenna & Harrison Inc. Method of using gonadorelin for the treatment of benign prostatic hyperplasia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2450109B1 (en) * 1977-11-08 1986-03-28 Roussel Uclaf NOVEL TREATMENT METHOD USING LH-RH, OR AGONISTS
NZ188987A (en) * 1977-11-30 1982-02-23 Salk Inst For Biological Studi Peptide analogues of luteinizing hormone releasing factor
IT1149971B (en) * 1979-06-11 1986-12-10 Syntex Inc NONAPEPTIDE AND DECAPEPTIDE DERIVATIVES OF THE HORMONE THAT RELEASES THE LUTEINIZING HORMONE
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
FR2465486A1 (en) * 1979-09-21 1981-03-27 Roussel Uclaf NEW APPLICATION USING LH-RH OR AGONISTS
US4253997A (en) * 1979-12-17 1981-03-03 American Home Products Corporation Anti-ovulatory decapeptides
US4410514A (en) * 1982-12-06 1983-10-18 The Salk Institute For Biological Studies GnRH Agonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010149A (en) * 1974-04-26 1977-03-01 Sankyo Company Limited Analogs of LH-RH and process for preparing the same
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4071622A (en) * 1976-02-11 1978-01-31 Abbott Laboratories Treatment of a mammary or DMBA inducible tumor
US4034082A (en) * 1976-03-01 1977-07-05 Abbott Laboratories Method to prevent reproduction in warm-blooded female animals with nonapeptides
US4218439A (en) * 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4321260A (en) * 1980-05-22 1982-03-23 Ayerst, Mckenna & Harrison Inc. Method of using gonadorelin for the treatment of benign prostatic hyperplasia

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Borgmann, The Lancet, May 15, 1982, pp. 1097 1099. *
Borgmann, The Lancet, May 15, 1982, pp. 1097-1099.
Redding (1982) PNAS 79: 1273 1276. *
Redding (1982) PNAS 79: 1273-1276.
Schally (1971) Biochem. Biophys. Res. Comm. 43: 393, 1334. *
Tolis (1982) PNAS 79: 1658 1662. *
Tolis (1982) PNAS 79: 1658-1662.

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
AT397035B (en) * 1987-09-21 1994-01-25 Debiopharm Sa BIOERODABLE PHARMACEUTICAL COMPOSITION FOR LASTING AND CONTROLLED POLYPEPTIDE RELEASE
WO1989007450A1 (en) * 1988-02-10 1989-08-24 Abbott Laboratories Lhrh analogs
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
US5084443A (en) * 1989-12-04 1992-01-28 Biomeasure, Inc. Promoting expression of acetylcholine receptors with lhrh antagonist
US5284657A (en) * 1991-08-26 1994-02-08 Abbott Laboratories Compositions and methods for the sublingual or buccal administration of therapeutic agents

Also Published As

Publication number Publication date
ZA854590B (en) 1986-02-26
PT80658B (en) 1986-12-09
DK615084D0 (en) 1984-12-20
CA1257950A (en) 1989-07-25
NZ212454A (en) 1988-09-29
DK615084A (en) 1985-12-19
EP0171477A3 (en) 1987-10-14
PT80658A (en) 1985-07-01
AU4376485A (en) 1986-01-02
ES8702438A1 (en) 1987-01-01
EP0171477A2 (en) 1986-02-19
FI850193A0 (en) 1985-01-16
NO852439L (en) 1985-12-19
FI850193L (en) 1985-12-19
ES544316A0 (en) 1987-01-01
JPS617297A (en) 1986-01-13

Similar Documents

Publication Publication Date Title
US5171835A (en) LHRH antagonists
US4010125A (en) [D-Trp6 ]-LH-RH and intermediates therefor
US4866160A (en) Therapeutic decapeptides
US4410514A (en) GnRH Agonists
US4689396A (en) GnRH antagonists V
EP0973801B1 (en) GnRH ANTAGONISTS
IE63707B1 (en) Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4690916A (en) Nona and decapeptide analogs of LHRH useful as LHRH antagonists
WO1991005563A1 (en) Therapeutic decapeptides
JPH0371439B2 (en)
US4253997A (en) Anti-ovulatory decapeptides
US5073624A (en) Therapeutic decapeptides
US4018726A (en) [D-Phe6 ]-LH-RH and intermediates therefor
US4632979A (en) Therapeutic LHRH analogs
CA1067487A (en) Lh-rh analogs and intermediates therefor
EP0081877A1 (en) LH-RH antagonists
US4581169A (en) Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4721775A (en) Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
EP0041286B1 (en) Lh-rh antagonists
CA1243307A (en) Peptides affecting gonadal function
EP0225746A2 (en) Therapeutic decapeptides
EP0197798B1 (en) Peptides
EP0301850A2 (en) LHRH antagonist analogs and 19-nor-progestational steroids for therapy
GB2053229A (en) LH-RH antagonists
EP0364819A2 (en) LHRH analogs

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, NEW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:COY, DAVID H.;MOREAU, JACQUES-PIERRE;REEL/FRAME:004275/0295;SIGNING DATES FROM 19840509 TO 19840516

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19950104

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362